Cache Dna
Founded 2021 · 74 employees on LinkedIn · 6 known investors
Cache develops a platform for reliable long-term storage and access of biomolecules to support precision medicine and fundamental research. It aims to provide scalable, sustainable, and standardized biomolecule storage.
Also known as Cache · Cache DNA · Cache DNA, Inc.
Investors · 6
.jpeg){kind=logo}
Company profile
researched Aug 2026Cache DNA, Inc. develops biopreservation reagents intended to allow DNA, RNA and other biological samples to be stored and retrieved at ambient temperature, removing the need for freezers, dry ice and other cold-chain infrastructure. The company frames its aim as a scalable, sustainable and standardized platform for reliable long-term storage and access of biomolecules, positioned as an enabling layer for research, drug development, diagnostics and precision medicine.
The stated technical rationale is that freezer-dependent workflows introduce cost, operational complexity and pre-analytical variability, since freeze-thaw cycles and time-sensitive sample preparation can differ between tests and batches. Working at room temperature is presented as a way to remove those variables while reducing consumption of energy, space and consumables. The reagents are described as compatible with a range of sample types, including high molecular weight human genomes, plant transcriptomes, plasmids and synthetic oligonucleotides, with preservation acting as a reversible pause on the sample.
Founding story
Mark Bathe, PhD, is listed as Cache's scientific founder. The technology traces to published work on silica-based DNA preservation co-authored by James Banal and Mark Bathe.
Business model
Cache develops and supplies biopreservation reagents and related products for laboratory sample storage workflows.
▸Full profile — market position, technology, go-to-market, history
Market position
Cache positions its ambient-temperature preservation reagents as an alternative to freezer- and dry-ice-based biospecimen storage, targeting reduced cost, complexity, quality risk and waste at scale.
Technology
Cache's platform is based on patented biopreservation reagents and has moved through three generations described by the company: a first-generation silica chemistry ("FOSSIL"), a second-generation polymer chemistry ("RAPTOR"), and a third-generation aqueous reagent ("CRADLE"). The Cradle chemistry is described as an "add-n-done" workflow designed to be dropped into existing laboratory processes. The company references supporting peer-reviewed work and conference presentations, including papers in ACS Applied Materials & Interfaces and Nature Materials (2021), Trends in Genetics (2025) and Nucleic Acids Research (2026), plus presentations at ACMG, ISBER, SLAS and AGBT between 2024 and 2026. A demo kit protocol for the earlier silica chemistry is listed as deprecated.
Go-to-market
Cache offers an early access program for prospective users alongside published product and technology documentation, and directs inquiries to a general company contact address.
The company states it works with scientists, biotech organizations and industry partners seeking to modernize biospecimen storage and simplify sample logistics, with applications spanning biomedical research, diagnostics, personalized medicine and environmental sampling.
History
The company's technology has progressed through successive reagent generations — silica chemistry (V1, "FOSSIL"), polymer chemistry (V2, "RAPTOR") and an aqueous reagent (V3, "CRADLE") — with associated publications and conference presentations dated from 2021 through 2026.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2022 | $255.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
▸Research sources · 7
primary sources listed
- Cache Dnacache-dna.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Cache Dna do?
- Cache DNA develops biopreservation reagents that allow DNA, RNA and other biosamples to be stored at room temperature.
- Who are Cache Dna's investors?
- Cache Dna's investors include Fifty Years, HAWKTAIL, Juniper, LifeX Ventures, Trousdale Ventures, Valkyrie.